Effektivnost' blokady renin-angiotenzin-al'dosteronovoy sistemy u bol'nykh sakharnym diabetom 2-go tipa s diabeticheskoy nefropatiey
- Authors: Trubitsyna N.P1, Katsaya G.V1, Goncharov N.P1, Il'in A.V1, Nikankina L.V1, Shamkhalova M.S.1, Shestakova M.V1
-
Affiliations:
- ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
- Issue: Vol 9, No 9 (2007)
- Pages: 61-64
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/92447
- ID: 92447
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N. P Trubitsyna
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
G. V Katsaya
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
N. P Goncharov
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
A. V Il'in
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
L. V Nikankina
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
M. Sh Shamkhalova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
M. V Shestakova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
References
- The ACE Inhibitors in Diabetic Nephropathy Trialist Group. A meta analysis of individual patients data. Ann Intern Med 2001; 134: 370–9.
- Hollenberg N.K, Fisher N.D, Price D.A. Pathways for angiotensin II generation in intact human tissue evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387–92.
- Danilczyk U, Penninger J.M. Angiotensin - converting Enzyme II in the heart and the kidney. Circulation Research 2006; 98: 463–85.
- Renal redox stress and remodeling in metabolic syndrome, type 2 diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005; 25: 553–69.
- Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart fail ure. Eur Heart J 2000; 21: 53–7.
- van de Wal R, Plokker T, Lok D et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int Cardi ol 2006; 106: 367–72.
- Duprez D.A. Role of renin - angiotensin aldosterine system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24: 983–91.
- Mulatero P, Milan A, Williams T.A et al. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 2006; 4: 75–91.
- Sato A, Hayashi K, Naruse M et al. Effec tiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64–8.
- Burnier M, Zanchi A. Blockade of renin - angiotensin - aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular event in patients with diabetes. J Hypertens 2006; 24: 11–25.